News & Media

Intelligent Fingerprinting Limited’s commercial-stage, revenue-generating platform technology would provide an expanded product upon which to leverage the existing GBS pipeline New York, NY, June 16, 2022 (GLOBE NEWSWIRE) – GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point of care, today announced that…

New York, NY, March 31, 2022 – GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced it has obtained Institutional Review Board (IRB) approval to initiate subject enrollment at the Diabetes Research Institute of Sutter Health’s Mills-Peninsula Medical Center (MPMC)…

New York, NY, November 30, 2021 – GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced it will commence preparation for clinical trials of its rapid SARS-CoV-2 Antibody test following the recent successful completion of a clinical validation study. As…

In all target markets, 90% of patients responded positively to the Biosensor Platform technology. Seven out of 10 patients were “seriously interested” in purchasing the product when it’s released. Additionally, GBS found that patients in China indicated that price was not an issue, as long as the product was accurate and reliable Sublicensing to a…

Intelligent Bio Solutions Inc. was formerly known as GBS Inc. New York, NY, July 8, 2021 – GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced it has been awarded a USD $4.7 million, Australian Federal Government science grant to fund…

New York, NY, June 7, 2021 – GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced survey results from more than 300 patients globally as part of its development and go-to-market strategy. As GBS is advancing to clinical trials of…

NEW YORK APRIL 15, 2021 – GBS, Inc. (GBS), a life sciences company developing non-invasive, real-time point-of-care (POC) diagnostic tests, and the Wyss Institute for Biologically Inspired Engineering at Harvard University (Wyss Institute) have received approval from the Harvard Longwood campus Institutional Review Board (IRB) to commence a validation study to test clinical samples from…

New York, NY, February 18, 2021 – GBS Inc. (Nasdaq: GBS), a life sciences company that develops non-invasive, real-time point of care (POC) diagnostic tests for patients and their primary health practitioners, today announced the execution of a sponsored research agreement with Johns Hopkins Bloomberg School of Public Health to accelerate development of next-generation saliva-based diagnostic tests….

This article has been republished with permission from the Wyss Institute at Harvard University. Click here to view the original article. By Benjamin Boettner (BOSTON) — The Wyss Institute for Biologically Inspired Engineering at Harvard University and GBS Inc., a subsidiary of The iQ Group Global, announce that they will collaborate to validate and de-risk…

SYDNEY – May 29, 2020 Life Science Biosensor Diagnostics Pty Ltd (LSBD), a development company of The iQ Group Global, entered into a development collaboration agreement with the Wyss Institute for Biologically Inspired Engineering at Harvard University this week to develop the test from the Australian-invented Biosensor Platform; a printable organic thin-film transistor ‘strip’ being developed by LSBD to…

SYDNEY – February , 2019 – The iQ Group Global, a consortium of life science and financial services companies which span the biopharma value chain from asset discovery to commercialization, today introduced the Saliva Glucose Biosensor. This groundbreaking technology is the world’s first non-invasive, saliva-based glucose test for diabetes management that measures glucose in saliva…